+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

  • ID: 5024757
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 552 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Cambryn Biologics LLC
  • ethris GmbH
  • Invion Ltd
  • Novabiotics Ltd
  • Respiratorius AB
  • MORE
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 38, 15, 3, 77, 21 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Cambryn Biologics LLC
  • ethris GmbH
  • Invion Ltd
  • Novabiotics Ltd
  • Respiratorius AB
  • MORE
  • Introduction
  • Chronic Obstructive Pulmonary Disease (COPD) - Overview
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
  • Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
  • Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
  • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2020
List of Figures
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • AB Science SA
  • AB2 Bio Ltd
  • Adamis Pharmaceuticals Corp
  • Afimmune Biopharma Ltd
  • Aibios Co Ltd
  • AlgiPharma AS
  • Allinaire Therapeutics LLC
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • Apollo Therapeutics LLC
  • Aquilon Pharmaceuticals SA
  • Aridis Pharmaceuticals Inc
  • Ark Biosciences Inc
  • AstraZeneca Plc
  • AusBio Ltd
  • Avidin Ltd
  • Axolo Pharma Inc
  • Bai Shuo Beijing Pharmaceutical Technology Co Ltd
  • Bayer AG
  • BioMarck Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • C4X Discovery Holdings Plc
  • Cambryn Biologics LLC
  • Celon Pharma SA
  • Chiesi Farmaceutici SpA
  • China Resources Pharmaceutical Group Ltd
  • Cipla Ltd
  • Circassia Pharmaceuticals Plc
  • Covenant Therapeutics LLC
  • CSL Ltd
  • Cureveda LLC
  • Cytokinetics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Denovo Biopharma LLC
  • Diffusion Pharmaceuticals Inc
  • Dimerix Ltd
  • Domainex Ltd
  • EmeraMed Ltd
  • EmphyCorp Inc
  • Emphymab Biotech LLC
  • Enzychem Lifesciences Corp
  • EpiEndo Pharmaceuticals Ehf
  • Epitracker Inc
  • Errant Gene Therapeutics LLC
  • ethris GmbH
  • Evaxion Biotech ApS
  • Exotect LLC
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Future Medicine Co Ltd
  • Galapagos NV
  • GeneFrontier Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Grifols SA
  • iCeutica Inc
  • Icure Pharmaceutical Inc
  • InMed Pharmaceuticals Inc
  • Inmunotek SL
  • Insmed Inc
  • Invion Ltd
  • Ionis Pharmaceuticals Inc
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • KBP BioSciences Co Ltd
  • Kither Biotech Srl
  • Korea United Pharm Inc
  • Koutif Therapeutics LLC
  • Kyowa Kirin Co Ltd
  • LTT Bio-Pharma Co Ltd
  • Mariposa Health Ltd
  • MD Healthcare Inc
  • Mereo Biopharma Group Plc
  • Meridigen Biotech Co Ltd
  • Metagone Biotech Inc
  • MetrioPharm AG
  • Naegis Pharmaceuticals Inc
  • NB Health Laboratory Co Ltd
  • Novabiotics Ltd
  • Novartis AG
  • Omnispirant Ltd
  • OncoArendi Therapeutics SA
  • Oncostellae SL
  • Orchid Pharma Ltd
  • Orphomed Inc
  • Palo BioFarma SL
  • PharmaLundensis AB
  • Pharmaxis Ltd
  • Prous Institute for Biomedical Research SA
  • Pulmatrix Inc
  • Pulmotect Inc
  • Qu Biologics Inc
  • Quark Pharmaceuticals Inc
  • Re-Pharm Ltd
  • Regeneron Pharmaceuticals Inc
  • Resolys Bio Inc
  • Respiratorius AB
  • Rhizen Pharmaceuticals SA
  • Santhera Pharmaceuticals Holding AG
  • Silurian Pharmaceuticals Inc
  • Silver Valley Pharmaceutical Co Ltd
  • SolAeroMed Inc
  • Sparrow Pharmaceuticals Inc
  • sterna biologicals Gmbh & Co KG
  • Sulfateq BV
  • Suzhou Connect Biopharmaceuticals Ltd
  • Symmune Therapeutics LLC
  • Synairgen Plc
  • Synovo GmbH
  • Syntrix Biosystems Inc
  • Taiho Pharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd
  • TFF Pharmaceuticals Inc
  • TGV-Inhalonix Inc
  • Theratrophix LLC
  • Torrent Pharmaceuticals Ltd
  • Unity Biotechnology Inc
  • Verona Pharma Plc
  • Verra Therapeutics LLC
  • Vicenna Pharmaceuticals Inc
  • vTv Therapeutics Inc
  • Yungjin Pharm Co Ltd
  • Zai Lab Ltd
Note: Product cover images may vary from those shown
Adroll
adroll